Pluri Inc. Logo

Pluri Inc.

PLUR | TA

Overview

Corporate Details

ISIN(s):
US72942G2030
LEI:
Country:
Israel
Address:
Park Building No. 5, 3508409 Haifa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company that researches, develops, and manufactures cell-based products and therapeutics. The company specializes in its proprietary 3D cell-expansion technology platform, which is used to create solutions for commercial use aimed at improving human well-being and sustainability. Pluri develops products from placenta-based cells for applications across the medical and pharmaceutical industries, often in collaboration with research partners and academic institutions.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pluri Inc.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-03 22:43
Post-Annual General Meeting Information
Immediate Report
Hebrew (modern) 224.6 KB
2025-07-03 22:43
Foreign Filer Report
Immediate Report
English 36.5 KB
2025-07-02 01:15
Director's Dealing
Other Report or Announcement
English 267.8 KB
2025-07-02 01:15
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-05-28 21:57
Proxy Solicitation & Information Statement
mediate Report of Meeting to be held on June 30, 2025
English 1.4 MB
2025-05-28 21:57
Pre-Annual General Meeting Information
mediate Report of Meeting to be held on June 30, 2025
English 184.6 KB
2025-05-28 01:52
Annual Report
Materials for Annual Meeting - Annual Report for 30.06.2024
English 346.4 KB
2025-05-28 01:52
Foreign Filer Report
Materials for Annual Meeting - Annual Report for 30.06.2024
English 36.3 KB
2025-05-28 01:36
Proxy Solicitation & Information Statement
Immediate Report of Meeting to be held on June 30, 2025, proxy
English 1.4 MB
2025-05-28 01:36
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on June 30, 2025, proxy
English 161.1 KB
2025-05-27 17:56
Pre-Annual General Meeting Information
FORM 8K – Updated Regurding Annual Meeting Date
English 112.3 KB
2025-05-27 17:56
Foreign Filer Report
FORM 8K – Updated Regurding Annual Meeting Date
English 36.3 KB
2025-05-20 17:26
Major Shareholding Notification
Form 13D/A-Yaky Yanay
English 168.9 KB
2025-05-20 17:26
Foreign Filer Report
Form 13D/A-Yaky Yanay
English 36.2 KB
2025-05-15 16:02
Management Discussion and Analysis
Pluri CEO Issues Shareholder Letter
English 110.5 KB

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
TheraVet SA Logo Belgium ALVET
Thor Medical ASA Logo
Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.
Norway NANOV
Tikun Olam Cannbit Pharmaceuticals Ltd. Logo
Vertically integrated R&D and production of clinically-validated medical cannabis treatments.
Israel TKUN
TMS Co., Ltd Logo Japan 4891
Together Pharma Ltd. Logo
Researches and produces medical cannabis products for domestic and European patients.
Israel TGTR
Japan 4551
TOWA PHARMACEUTICAL CO.,LTD. Logo Japan 4553
TSUMURA & CO. Logo Japan 4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish pharma producer of human medicines, vaccines, and high-capacity IV solutions (serum).
Türkiye TRILC
UCB Logo
UCB
A biopharmaceutical firm developing therapies for severe neurological and immunological diseases.
Belgium UCB